Loading...
Ph II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in patients with advanced NSCLC
Arce-Lara, C Arriola, E Brunsvig, P Carcereny, E Domine, M Dragnev, K Felip, E Campelo, R Krebs, Matthew G Paz-Ares, L
Arce-Lara, C
Arriola, E
Brunsvig, P
Carcereny, E
Domine, M
Dragnev, K
Felip, E
Campelo, R
Krebs, Matthew G
Paz-Ares, L
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Arce-Lara C, Arriola E, Brunsvig P, Carcereny E, Domine M, Dragnev K, et al. P2.04-27 Ph II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in patients with advanced NSCLC. J Thorac Oncol. 2018;13(10):S741.